First Data Show In Vivo CAR T Therapy Helps Lymphoma Patients

A new CAR T therapy that is made inside the body has shown early promise for hard to treat B cell non Hodgkin lymphoma. The treatment, called CT1182, targets both CD19 and CD20 on lymphoma cells and is built on the CARvivo platform from CARsgen Therapeutics. Unlike standard CAR T therapy, it does not require removing cells, engineering them in a lab and returning them weeks later. In the early dose trial, six patients could be assessed for response and five responded, with three complete responses and two partial responses. The responses were still ongoing at the October 31 data cut, which is encouraging for a small early study. Safety also looked favourable, with no dose limiting toxicities, no treatment related serious events and only mild Grade 1 cytokine release syndrome. Larger trials will now need to confirm whether the benefit lasts and whether the simpler approach can reach more patients.

image
advertisement
"We will never ask you to login, or register through a third-party advertisement."